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On the diversity of biological therapeutics
Increasingly precise deﬁ  nition of the molecular nature of disturbances in cellular 
homeostasis that characterize different disease is leading to an astounding array of 
novel and effective therapeutics. These are appearing at a rate unrivaled in history. 
Certainly, not all of these are simply the product of new development. For instance, 
the idea of enzyme replacement therapy has long roots, but advances in recombinant 
protein production and delivery techniques have led to successful implementation 
of enzyme replacement therapy; dosing is being optimized in clinical studies, and it 
appears that greater beneﬁ  t will be realized with earlier therapy. 
Certainly, enzyme inhibition is much simpler and more traditionally rooted in 
pharmacology. Remarkable success has been achieved using designer small molecule 
enzyme inhibitors. Increasingly reﬁ  ned small molecules such as imatinib, geﬁ  tinib, 
and tipifarnib, discussed in the present issue, are a testament to the signiﬁ  cant of basic 
discoveries, the ingenuity of drug-designers, and hard work of translational researchers 
across pharma, academia, and communities. 
Though dramatic progress has been made in the treatment of relatively uncommon 
disease with narrowly deﬁ  ned etiology, progress is less spectacular in development of 
targeted therapeutic for the more common disease, which have complex, multifactorial, 
and as yet incompletely deﬁ  ned mechanisms at the molecular level of pathophysiology. 
Modest improvements have been seen in solid-tumor therapeutic with wider implemen-
tation of biological therapeutics such as bevacizumab. The efﬁ  cacy of targeted therapy 
for inﬂ  ammatory disorders, such as rheumatoid arthritis and psoriasis, far exceeds 
the efﬁ  cacy of targeted therapeutics for common solid malignancies. Perhaps this is 
because inﬂ  ammatory disorders result form speciﬁ  c and relatively well characterized 
disturbances in immune effector cells, in the background of an essentially normal and 
functional genome and proteome. In contrast, genomic instability, and much more 
random and diverse array of defects that give rise to cancer are understandably more 
difﬁ  cult even to fully characterize, much less target effectively with a single agent. 
Despite these limitations, solid tumor therapy has improved considerably, as evident 
in improving survival rates for disease in which conventional chemotherapy had only 
marginally affected overall survival. 
The paradigms from the targeted therapy of rare and uncommon diseases with 
highly speciﬁ  c and effective agents can perhaps be applied to effective use of thera-
peutics for the more common solid malignancies. Increasingly precise deﬁ  nition of 
the signiﬁ  cance of mutations in the EGF-receptor and tyrosine-kinases as well as 
other targets may soon allow widespread implementation of selectively targeting 
subgroups of common solid neoplasms. Such therapies have already caused de-facto 
reclassiﬁ  cation of common neoplastic diseases into subcategories deﬁ  ned by muta-
tions or protein-expression changes, and has already dramatically altered treatment 
paradigms, particularly in breast, colon and lung cancer. As with uncommon or rare 
neoplasms such as cutaneous T-cell lymphoma, chronic myelogenous leukemia or 
dermatoﬁ  brosarcoma protuberans, the subcategorized neoplasms of breast, lung or 
colon can also be exquisitely sensitive to speciﬁ  cally targeted therapies.
However, unlike inﬂ  ammatory disorders, combination of targeted therapeutics will 
likely be necessary to achieve a similar level of efﬁ  cacy in solid tumors. Unfortunately, 
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there are too may potential combinations, and pre-clinical 
algorithms for predicting the most efﬁ  cacious combina-
tion are yet in their infancy. These efforts have been, and 
will likely continue to be led astray if methods of target 
identiﬁ  cation and elucidation of signaling pathway con-
nections rely too heavily on genomics, without necessary 
attention to the context of metabolic pathways, enzymes, 
and post-translational modiﬁ  cations, which can be deﬁ  ned by 
proteomics. Empiric combination therapies based on clinical 
observations of astute observers remains a welcome means 
of discovery of optimal combinations. In the present issue, 
the report of using geﬁ  tinib and radiation for carcinomatous 
encephalitis is intriguing in this respect, and suggest a clini-
cally utilizable general radiosensitizing effect of geﬁ  tinib, if 
conﬁ  rmed in larger controlled studies. 
The idea of combining multiple targeted therapeutics to 
treat disorders of complex pathophysiology is extended to 
asthma by the though provoking article by Popescu (2007). 
Such therapeutics could promise the potential of a relatively 
long-term remission from asthma without even the need 
for rescue medications. The issues regarding systemic or 
local adverse reactions would be exponentially magniﬁ  ed 
by multi-targeting. Insufﬁ  cient knowledge of the effects of 
such interventions on cellular metabolic pathways could 
potentially result in combinations that are inherently an-
tagonistic. We need not look far to ﬁ  nd examples where 
combining targeted biologicals has not improved efﬁ  cacy. 
There are no clear-cut explanations to the observations 
regarding the relative failure of targeted therapeutics, 
other than the obvious complexity of disease pathology, 
or inaccurate models of signaling that have poorly deﬁ  ned 
connections to metabolic pathways or cellular processes. In 
the face of these obstacles, it is reassuring that discovery of 
novel therapeutic combinations could result from ingenious 
cross-disciplinary collaborations that are subject of several 
articles in the current issue.
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